P673 The safety of rapid versus standard infliximab infusions in children with inflammatory bowel disease: a multi-centre retrospective cohort study

Jagt, J.(1,2)*;Galestin, S.(3);Benninga, M.(1);de Boer, N.(4);de Meij, T.(1);

(1)Amsterdam UMC- location University of Amsterdam, Department of Pediatric Gastroenterology and Nutrition, Amsterdam, The Netherlands;(2)Amsterdam UMC- Vrije Universiteit Amsterdam, Pediatric Gastroenterology- Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands;(3)Amsterdam UMC- location University of Amsterdam, Faculty of Medicine, Amsterdam, The Netherlands;(4)Amsterdam UMC- Vrije Universiteit Amsterdam, Department of Gastroenterology and Hepatology- Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam, The Netherlands;


Rapid infliximab (IFX) infusions have shown to be safe in adults with inflammatory bowel disease (IBD), but data on its safety in paediatric IBD is limited. This study aimed to assess the frequency and timing of infusion reactions (IR) in children with IBD who received rapid (1-h) vs. standard (2-h) IFX infusions.


This retrospective cohort study included IBD patients 4-18 years old, treated with IFX between January 2006 - November 2021 at two tertiary centres (AMC and VUmc) in Amsterdam, the Netherlands. The AMC protocol was adjusted from standard to rapid infusions with a 1-h post-infusion observation period in July 2019, whereas in VUmc only standard infusions were administered without a post-infusion observation period. After merging both departments in 2022, VUmc patients were allocated from standard to rapid infusions. The primary outcome was the frequency of acute IR amongst rapid vs. standard infusions. Secondary outcomes were the timing, severity and management of IR.


Totally, 297 (150 VUmc, 147 AMC) patients (221 Crohn’s disease; 65 ulcerative colitis; 11 IBD-unclassified) were included, with a total of 7500 maintenance IFX-infusions. No differences were found in the frequency of IR between the patients receiving standard infusions (16/115, 13.9% of patients), rapid infusions (1/31, 3.2%) and both infusion rates (11/151, 7.3%) (p= 0.105). No difference in the frequency of IR was found between standard infusions (26/4383, 0.6% of infusions) and rapid infusions (9/3117, 0.3%) (p= 0.083). Twenty-six of 35 IR (74.3%) occurred during infusion, while nine occurred post-infusion (25.7%). All post-infusion IR were mild, requiring no intervention or oral medication.


Rapid IFX infusions did not result in an increased frequency of IR compared to standard infusions. The IR that occurred post-infusion were mild. Our data have resulted in adjustment of the protocol to rapid infusion without a post-infusion observation period for all IFX patients.